Effect of rectal indomethacin on the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography for choledocholithiasis: a prospective randomized clinical trial

Background and aim: the aim of this study was to evaluate the efficacy and safety of rectal indomethacin for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in patients with common bile duct (CBD) stones. Methods: a total of 167 patients undergoing ERCP between November 2019 and November 2022 for CBD stones in the First Affiliated Hospital of Dalian Medical University were prospectively analyzed. The patients were divided into an indomethacin group (n = 58) and a control group (n = 109). The primary endpoint was the percent of patients who experienced PEP. Results: PEP was observed in a total of 26 patients (15.57 %); four patients (6.90 %) in the indomethacin group and 22 (20.18 %) in the control group (p = 0.042). Mild, moderate and severe PEP was observed in three (5.17 %), one (1.72 %) and zero patients, respectively, in the indomethacin group, and in eleven (10.09 %), nine (8.26 %) and two (1.83 %) patients, respectively, in the control group. There was one case (0.92 %) of death due to PEP in the control group. No cases of moderate or severe bleeding were observed in either group. Conclusions: rectal indomethacin is an effective and safe method to prevent PEP for patients with CBD stones undergoing ERCP. (AU)

Effect of rectal indomethacin on prevention of pancreatitis after ERCP for choledocholithiasis: a prospective randomized clinical trial.

BACKGROUND AND AIM: The aim of this study is to evaluate the efficacy and safety of rectal indomethacin for prevention of post-ERCP pancreatitis (PEP) in patients with common bile duct (CBD) stones. METHODS: A total of 167 patients undergoing ERCP between November 2019 and November 2022 for CBD stones in the First Affiliated Hospital of Dalian Medical University were prospectively analyzed. The patients were divided into an indomethacin group (n=58) and a control group (n=109). The primary endpoint was the percent of patients who experienced PEP. RESULTS: PEP was observed in a total of 26 patients (15.57%): 4 patients (6.90%) in the indomethacin group and 22 (20.18%) in the control group (p=0.042). Mild, moderate, and severe PEP was observed in 3 (5.17%), 1 (1.72%), and 0 patients, respectively, in the indomethacin group and in 11 (10.09%), 9 (8.26%), and 2 (1.83%) patients, respectively, in the control group. One case (0.92%) of death due to PEP was observed in the control group. No cases of moderate or severe bleeding were observed in either group. CONCLUSIONS: Rectal indomethacin is an effective and safe method to prevent PEP for patients with CBD stones undergoing ERCP.